Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA9 | Q16790 | 17/20 | 0.44 |
| ▸ | CA12 | O43570 | 16/20 | 0.44 |
| ▸ | CA1 | P00915 | 11/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 4/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.39 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.39 |
| ▸ | ABCC2 | Q92887 | 1/20 | 0.39 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.39 |
| ▸ | UGT1A7 | Q9HAW7 | 1/20 | 0.39 |
| ▸ | SLC22A11 | Q9NSA0 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7650712 | 0.92 | CA9 (0.45) | CA9CA12CA1KDM4EALDH1A1 | |
| SCHEMBL7649007 | 0.91 | KDM4E (0.43) | CA9CA12CA1KDM4EALDH1A1 | |
| SCHEMBL6934329 | 0.84 | CA9 (0.46) | CA9CA12CA1KDM4EALDH1A1 | |
| SCHEMBL6940270 | 0.82 | KAT6A (0.44) | CA9CA12CA1CA2 | |
| SCHEMBL7653443 | 0.82 | CA9 (0.42) | CA9CA12CA1KDM4EALDH1A1 | |
| SCHEMBL7652678 | 0.82 | KDM4E (0.38) | KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL7653447 | 0.81 | CA9 (0.40) | CA9CA12CA1KDM4EALDH1A1 | |
| SCHEMBL7647451 | 0.78 | BCAT1 (0.38) | KDM4EALDH1A1 | |
| SCHEMBL6935413 | 0.76 | CA9 (0.43) | CA9CA12CA1KDM4EALDH1A1 | |
| SCHEMBL7645895 | 0.75 | BCAT1 (0.39) | CA9CA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1125942-B1 | Derivatives of 6-amino or 6-hydrazinosulfonyl-3-quinolyl phosphonic acids, process for their preparation and pharmaceutical compositions containing them | SERVIER LAB (FR) | 2003-04-09 | — | — | EP | claimed |
| US-6486143-B2 | NERVOUS SYSTEM DISORDERS; PSYCHOLOGICAL DISORDERS | LES LABORATOIRES SERVIER (FR) | 2002-11-26 | — | — | US | claimed |
| US-20010031746-A1 | 6-amino- or 6-hydrazino-sulphonyl-3-quinolynyl-phosphonic acid compounds | LES LABORATOIRES SERVIER (FR) | 2001-10-18 | — | — | US | claimed |
| US-6486143-B2 | NERVOUS SYSTEM DISORDERS; PSYCHOLOGICAL DISORDERS | LES LABORATOIRES SERVIER (FR) | 2002-11-26 | — | — | US | disclosed |
| US-20010031746-A1 | 6-amino- or 6-hydrazino-sulphonyl-3-quinolynyl-phosphonic acid compounds | LES LABORATOIRES SERVIER (FR) | 2001-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010031746-A1 | 6-amino- or 6-hydrazino-sulphonyl-3-quinolynyl-phosphonic acid compounds | CA6, P2RY6, FPR3 | CA9 176/4885CA12 311/4885CA1 377/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.